Despite a promising approach for certain leukemia patients, the path to market appears to be in question.
| less than a minute read
This CD22 Approach Highlights the Importance of Experimental Medicine - and Collaboration
Get in touch
Get in touch
The therapy was developed at the National Cancer Institute, and Dr. Mackall said researchers did not know if a company would try to bring it to market.
Get in touch
Get in touch
Latest Insights
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-08-04-15-32-04-091-6a7205f4b4306b41266d92f2.jpg)
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-08-04-18-23-13-222-6a722e11663e81e26a6b2c3e.jpg)
